CologuardĀ® revenue increased 168 percent to $266 million

Go back to CologuardĀ® revenue increased 168 percent to $266 million

Exact Sciences (EXAS) Tops Q4 EPS by 6c

February 22, 2018 4:06 PM EST

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $87.4 million versus the consensus estimate of $85.74 million.

GUIDANCE:

Exact Sciences sees FY2018 revenue of $420-430 million, versus the consensus of $422.13... More